Research graph
References from Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers. Local targets link to admitted publications; unresolved targets remain external evidence.
Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
10.1016/s2215-0366(21)00395-3 · 2022 · External reference
Unresolved reference
External reference
Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications
2020 · External reference
Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales
10.1016/j.euroneuro.2014.01.014 · 2014 · External reference
Adverse effects of antipsychotic medications
2010 · External reference
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics
2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
The use of pharmacogenetic testing in patients with schizophrenia or bipolar disorder: A systematic review
10.9740/mhc.2018.11.294 · 2018 · External reference
Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial
10.1001/jamanetworkopen.2020.27909 · 2020 · External reference
A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments
10.1038/s41398-019-0511-9 · 2019 · External reference
A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics
10.1371/journal.pone.0162866 · 2016 · External reference
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
10.1093/schbul/13.2.261 · 1987 · External reference
Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions
2017 · External reference
Antipsychotic prescription pattern: A preliminary survey of Psychiatrists in India
10.4103/0019-5545.70982 · 2010 · External reference
Indian Psychiatric Society multicentric study: Prescription patterns of psychotropics in India
10.4103/0019-5545.140632 · 2014 · External reference
Clinical Practice Guidelines for Management of Schizophrenia
10.4103/0019-5545.196973 · 2017 · External reference
Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophrenia
10.1192/bjo.2021.945 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
A global reference for human genetic variation
10.1038/nature15393 · 2015 · External reference
The GenomeAsia 100K Project enables genetic discoveries across Asia
10.1038/s41586-019-1793-z · 2019 · External reference
Unresolved reference
External reference
Clinical Practice Guidelines for Management of Schizophrenia
10.4103/0019-5545.196973 · 2017 · External reference
Quantification of panel of most potent antipsychotic medicines by high throughput UPLC method
10.1016/j.rechem.2022.100427 · 2022 · External reference
Mental Health Care Act, 2017: How to organize the services to avoid legal complications?
10.4103/indianjpsychiatry.indianjpsychiatry_743_21 · 2022 · External reference
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients
10.1111/j.1600-0447.1987.tb10566.x · 1987 · External reference
Unresolved reference
1976 · External reference
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
10.1111/j.1532-5415.2005.53221.x · 2005 · External reference
Adverse effects of antipsychotic medications
2010 · External reference
Management of common adverse effects of antipsychotic medications
10.1002/wps.20567 · 2018 · External reference
SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects
10.1177/2045125313510195 · 2014 · External reference
Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation
10.1111/j.1464-5491.2006.01858.x · 2006 · External reference
Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia
2019 · External reference
Medication Adherence Using Electronic Monitoring in Severe Psychiatric Illness: 4 and 24 Weeks after Discharge
10.9758/cpn.2019.17.2.288 · 2019 · External reference
Unresolved reference
External reference
A multiple testing procedure for clinical trials
10.2307/2530245 · 1979 · External reference
Thresholds for the cost-effectiveness of interventions: alternative approaches
10.2471/blt.14.138206 · 2015 · External reference
Unresolved reference
External reference
National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India
10.1007/s40258-021-00668-y · 2021 · External reference
Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors
10.1517/14656566.9.12.2027 · 2008 · External reference
Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation
10.1371/journal.pone.0218711 · 2019 · External reference
A qualitative exploration of family members’ perspectives on reducing and discontinuing antipsychotic medication
10.1080/09638237.2022.2069710 · 2022 · External reference
Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness
10.1007/s11096-016-0352-z · 2016 · External reference
An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders
10.1186/s12888-022-03822-5 · 2022 · External reference
A qualitative exploration of perceived needs and barriers of individuals with schizophrenia, caregivers and clinicians in using mental health applications in Madhya Pradesh, India
10.1016/j.ssmmh.2022.100063 · 2022 · External reference
Characterising and justifying sample size sufficiency in interview-based studies: systematic analysis of qualitative health research over a 15-year period
10.1186/s12874-018-0594-7 · 2018 · External reference
A simple method to assess and report thematic saturation in qualitative research
10.1371/journal.pone.0232076 · 2020 · External reference
What CATIE found: results from the schizophrenia trial
10.1176/ps.2008.59.5.500 · 2008 · External reference
Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophrenia
10.1192/bjo.2021.945 · 2021 · External reference
